Introduction {#s1}
============

Diabetic peripheral neuropathy (DPN) is one of the most common comorbidities of diabetes. DPN is a complex and progressive disorder, characterized by symmetrical distal degeneration of peripheral nerves, leading to symptoms of pain and sensory loss. As the disease progresses, symptoms can improve, predisposing the patients to diabetic ulceration and non-traumatic amputation [@pone.0076113-Boulton1].

The prevalence of DPN varies considerably depending on the diagnostic techniques used and patients selection. Annalisa [@pone.0076113-Rubino1] reported that 14.1% of people with diabetes had DPN in UK and 23.1% in Italy respectively. In the US, approximately one-third of people with diabetes aged 40 or older were diagnosed as DPN [@pone.0076113-Agrawal1]. A recent study reported that 11% were diagnosed with DPN in young children, with short diabetes duration, and good diabetes control [@pone.0076113-Moser1].

The pathophysiology of DPN is thought to be related to multiple factors, including glucose levels, metabolic and vascular factor, lifestyle, environmental factors, and inheritability. Although the exact pathogenesis is uncertain, persistent hyperglycemia is considered as a fundamental risk factor in the development of DPN [@pone.0076113-Boulton1], [@pone.0076113-Perkins1]--[@pone.0076113-Wooten1], and several studies have shown that strict glycemic control can reduce the occurrence and progression of DPN [@pone.0076113-DahlJrgensen1]--[@pone.0076113-UK1]. Currently, pharmacologic agents used in the treatment of diabetic neuropathy are used empirically to control the painful symptoms, including low-dose tricyclic antidepressants, anticonvulsants such as gabapentin, phenytoin, lamotrigine, opioids and tramadol, topical analgesic (topical capsaicin), and nonsteroidal anti-inflammatory drugs. Studies also demonstrated benefits of vitamin B12 on symptomatic improvement of patients with DPN [@pone.0076113-Sun1]--[@pone.0076113-Yaqub1]. Aerobic physical activity may be effective at improving peripheral nerve function and glycemic control of DPN patients, preventing the onset or modifying the natural history of DPN [@pone.0076113-Sigal1]--[@pone.0076113-Balducci1]. However, it remains largely underutilized because patient adherence is an issue.

Traditional Chinese medicine (TCM) including Chinese herbal medicine (CHM), acupuncture and other non-medication therapies has been used widely in China for thousands of years. CHMs therapy for DPN have been developed empirically over the years, and is now still widely used in China and elsewhere. The evidence from clinical studies suggested that CHMs could reduce the symptoms, improve nerve conduction velocity of patients with DPN [@pone.0076113-WU1]. Pharmacological studies demonstrated that CHMs could reduce oxidative stress and free radicals, and inhibit the apoptosis [@pone.0076113-Zhang1]--[@pone.0076113-Ji1]; regulate the polyol pathway and related metabolic disorder, reduce the sorbitol content in cells [@pone.0076113-Zhang2]; activate protein kinase C [@pone.0076113-Gao1]--[@pone.0076113-Chen1]; inhibit the formation of advanced glycation endoproducts [@pone.0076113-Ma1]; increase neurotrophy factors level such as BDNF, NGF and insulin-like growth factor-1 [@pone.0076113-Chen1], [@pone.0076113-Wu1]--[@pone.0076113-Zeng1]; improve haemodynamics, and decrease the levels of endothelin and ehromboxane [@pone.0076113-Xue1]; decrease the production of inflammatory cytokines, and reduce the inflammatory reaction [@pone.0076113-Wang1]. Recently, Sun et al. [@pone.0076113-Sun2] reported that CHMs could exert the analgesic effect by reversing both the increased transient sodium currents and the reduced total potassium currents of painful diabetic neuropathy experimental rat model.

Owing to the significant health risk of DPN and the limitations of currently available conventional therapies, there have been a number of controlled studies over the past decade to evaluate the efficacy and safety of CHMs for DPN. Three systematic reviews addressing the efficacy of CHMs for DPN have also been published recently [@pone.0076113-Xu1]--[@pone.0076113-Chen3], and concluded that the total efficacy rate and NCV in CHMs group were better than that in control group. However, their conclusions are not scientifically sound because most of the primary trials included were of low methodological quality and the small number of trials were included in the meta-analysis. Moreover, many new data have been published. Therefore, it is worthwhile to undertake an update systematic review and meta-analysis to assess the efficacy and safety of CHMs for patients suffering from DPN.

Methods {#s2}
=======

Eligibility Criteria {#s2a}
--------------------

### Types of Studies {#s2a1}

We selected randomized controlled clinical trials (RCTs) that compared any CHM with non-CHM interventions for DPN patients, and included high-quality RCTs with Jadad score_3 or above in efficacy and safety analysis. Quasi-RCTs were not considered such as using the admission sequence for treatment allocation.

### Types of Participants {#s2a2}

Patients of any gender, age, or race/ ethnicity with diabetic peripheral neuropathy were included. The definition of diabetic neuropathy used in the studies had to accord with the following diagnostic criteria: (1) diabetes mellitus was diagnosed according to the internationally recognized criteria, such as the World Health Organization criteria [@pone.0076113-World1] or the American diabetes association criteria [@pone.0076113-American1]; (2) the patient had a predominantly distal symmetrical sensorimotor polyneuropathy of the limbs, including subjective complaints of pain, tingling, numbness, weakness, and reduced functioning of the peripheral nerves demonstrated by a nerve conduction test; (3) other causes of sensorimotor polyneuropathy were excluded.

### Types of Interventions {#s2a3}

The patients of the control group were given no intervention, placebo or conventional medicines. The patients at the treatment groups were given CHM interventions. We also included trials of Chinese herbal medicine plus conventional medicine versus conventional medicine alone. Studies comparing one with another form of CHM were excluded. The clinical trials were included regardless of length of treatment period and dosage of treatment. The CHM interventions were included regardless of single herbs, a compound of several herbs or a Chinese proprietary medicine. The mode of delivery was restricted to orally.

### Types of Outcome Measures {#s2a4}

The primary outcome measures of interest were the absolute values or changing of motor or sensory nerve conduction velocity after treatment. The secondary outcome measurements were clinical symptoms improvements such as the total efficacy rate, and adverse events reported in the study. Clinical efficacy is defined as the ability of CHM to prevent or reverse clinical symptoms related to DPN. The TCM syndrome score criteria of DPN were adopted based on Guideline for Clinical Trials of New Patent Chinese Medicines [@pone.0076113-Zheng1], including limb pain, numbness, sensory disturbances, dry mouth and polydipsia, fatigue and weakness, soreness and weakness of waist and knees, feverishness in palms and soles, tongue and fur, and pulse manifestation ([Table 1](#pone-0076113-t001){ref-type="table"}). The effective rate was conducted in accordance with the TCM syndrome score criteria [@pone.0076113-Zheng1], which classified clinical therapeutic effects into four categories as cure (TCM clinical symptoms and signs disappeared or almost disappeared, the TCM syndrome scores were decreased up to 91--100%), significant improvement (TCM clinical symptoms and signs significantly improved, the TCM syndrome scores were decreased at 71--90%), improvement (TCM clinical symptoms and signs improved, the TCM syndrome scores were decreased at 31--70%), no improvement (The TCM clinical symptoms and signs were not improved or aggravated, the TCM syndrome scores were decreased less than 30%). Moreover, it was dichotomized as effective (including the categories of cure, significant improvement, and improvement) and ineffective (including the category of no improvement). Other assessment criteria of clinical therapeutic effect made by other authors with comparable definitions were also considered.

10.1371/journal.pone.0076113.t001

###### The TCM syndrome score criteria of diabetic peripheral neuropathy.

![](pone.0076113.t001){#pone-0076113-t001-1}

  Items                                       TCM syndrome score criteria                                                                                                                                                                                                                    
  ------------------------------------------ ----------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
  Limb pain                                          asymptomatic                                               slight and occasional limb pain                                                        persistent limb pain that can be endured, and does not affect sleep                                  persistent limb pain, unbearable, and severe sleep disturbance
  Numbness                                           asymptomatic                                         slight and occasional numbness of toe/finger                                                   sustained numbness of toe/finger, not obvious after distracting                                                sustained numbness below the elbow/knee
  Sensory disturbances                               asymptomatic                                       pain/temperature sensation subsided to the wrist                                                        pain/temperature sensation subsided to knee/elbow                                                cold hands and feet to the wrist/Elbow or knee/ankle
  Dry mouth and polydipsia                           asymptomatic                                          dry mouth, slightly increased water intake                                                      dry mouth, increased water intake half times more than past                                        dry mouth, increased water intake than past 1 times or more
  Fatigue and weakness                               asymptomatic                                    (mild limb weakness, climbed upstairs with heavy legs                                    limb weakness sometimes mild and sometimes severe, heavy legs when walking the ground                 significant limb weakness, lower limb heaviness obviously when lifting the legs
  Soreness and weakness of waist and knees           asymptomatic                                     occasional soreness and weakness of waist and knees                               frequently soreness and weakness of waist and knees, can participate in activities of daily living             continuous soreness and weakness of waist and knees, liking to lay in bed
  Feverishness in palms and soles                    asymptomatic                                          occasional feverishness in palms and soles                                  someone who want to expose his/her own hands and feet outside bedding and clothing, frequently upset   feel comfortable only when hands and feet approached the cold object, vexation and restless
  Tongue and fur                                     asymptomatic           deep purple tongue or ecchymosis on tongue or tortuous, bluish and purplish sublingual collateral vessel                                                                                                         
  Pulse manifestation                             gentle and regular                               stringy pulse or deep and hesitant pulse or thready pulse                                                                                                                                 

Information Sources and Search {#s2b}
------------------------------

We searched Cochrane library, PubMed, EMBASE, China National Knowledge Infrastructure, VIP Journals Database, and Wanfang database until November 2012. The search strategy combined two facets: the condition (DPN) and the intervention (Chinese herbal medicine). The search terms used were (herbal-medicine OR herbs OR Chinese herbal medicine OR Chinese medicinal herb) AND (diabetic peripheral neuropathy OR diabetic neuropathy OR DPN). Chinese Databases were also searched using the above search terms in Chinese. We hand-searched Chinese journals that may publish potentially eligible studies and conference proceedings relevant to this topic. The reference lists of all relevant articles were searched for further studies.

Study Selection and Data Collection Process {#s2c}
-------------------------------------------

All articles were screened by two independent reviewers (Hao C.Z., Wu F.), who extracted data from the articles according to a standardized data extraction form, including patients, methods, interventions and outcomes. The reasons for inclusion and exclusion of studies were recorded accordingly at all stages. For eligible studies, two review authors (Hao C.Z., Wu F.) extracted the data independently. Disagreements were resolved through consultation with a third party author (Guo Y. or Zheng G.Q.).

Risk of Bias in Individual Studies {#s2d}
----------------------------------

For each included study, two reviewers (Hao C.Z., Wu F.) independently completed the Jadad scale for assessing methodological quality. Trials scoring 1 or 2 points are considered low quality and 3--5 points as high quality [@pone.0076113-Jadad1]. And the risk of bias was further assessed using the twelve criteria recommended by the Cochrane Back Review Group [@pone.0076113-Furlan1], the items were scored with "yes (+)", "no (−)", or "unsure (?)". Studies were categorized as having a "low risk of bias" when at least six of the 12 criteria were met. Disagreements were resolved by discussion between the two reviewers (Hao C.Z., Wu F.), with the opinion of a third party author (Guo Y. or Zheng G.Q.) if necessary.

Description of the CHMs {#s2e}
-----------------------

The selection criteria of high-frequency herbs in Treatment of DPN were those with cumulative frequencies over 50%.

Summary Measures and Synthesis of Results {#s2f}
-----------------------------------------

We synthesized the results in a meta-analysis. A fixed-effects model or random-effect model was used across the trials, and risk ratios with their 95% confidence intervals (CI) were calculated for dichotomous data. If continuous data were available, weighted mean difference or standardized mean difference was to be calculated using RevMan 5.1 software provided by the Cochrane Collaboration. Heterogeneity between trial results was tested using a standard chi-square test and we also calculated the I^2^ statistic. The two-tailed P values less than 0.05 were considered statistically significant. Where possible, we assessed potential publication bias using a funnel plot.

Results {#s3}
=======

Study Selection {#s3a}
---------------

We identified 1117 potentially relevant articles, and 781 articles were excluded because they were not reporting clinical trials, review, case report, or lacking comparison group. Of the remaining 336 articles, 173 were excluded because 89 adopted topical CHM in the treatment group, 19 adopted topical plus oral CHM, 5 adopted oral CHM plus acupuncture, 14 adopted Chinese herbal injections, 42 compared one type of CHM to another, 3 had no information about the formula of CHM, and 1 reported the same group of patients with another included article. Finally, 163 studies were left and assessed by the Jadad score. Ten articles scoring ≥3, involving a total of 653 participants met our inclusion criteria [@pone.0076113-Hu1]--[@pone.0076113-Liu2]. The screening process is summarized in a flow diagram ([Figure 1](#pone-0076113-g001){ref-type="fig"}).

![PRISMA 2009 Flow Diagram.](pone.0076113.g001){#pone-0076113-g001}

Study Characteristics {#s3b}
---------------------

The 10 studies included were all conducted in China and published between 2004 and 2012. Eight studies were performed in a single center while the other two studies [@pone.0076113-Heng1]--[@pone.0076113-Li2] were performed in multicenter. A total of 653 participants of Chinese ethnicity were included in the 10 studies, of whom 316 were male and 302 were female (the gender of the left 35 participants could not be obtained from the primary data) ranging from 25 to 71 years old. Among the 10 included studies, one was three-group design study, while the remaining 9 were two-group parallel design studies. The diagnostic criteria were based on the World Health Organization (WHO) criteria in 8 studies [@pone.0076113-Chen4]--[@pone.0076113-Heng1], [@pone.0076113-Liu2], and American Diabetes Association (ADA) criteria in the other 8 studies respectively [@pone.0076113-Hu1], [@pone.0076113-Li2].

Seven trials evaluated the effects of CHM compared to mecobalamin [@pone.0076113-Hu1]--[@pone.0076113-Cao1], [@pone.0076113-Zhou1]--[@pone.0076113-Zhang3], [@pone.0076113-Li2]--[@pone.0076113-Liu2]. However, the specific compositions of these herbal formulae were different in each of the 7 trials. One trial compared the effects of CHM plus pancreatin tablets to pancreatin tablets alone [@pone.0076113-Li1], and 2 trials evaluated the effects of the same CHM capsule compared to inositol [@pone.0076113-Liu1]--[@pone.0076113-Heng1]. Hypoglycemic therapy was used as a co-intervention in all the 10 included trials, including oral hypoglycemic drugs, insulin treatment, and exercise. The duration of treatment lasted from 6 weeks to 12 weeks. Adverse effects were reported in all of the 10 trials. Detailed characteristics of included studies were listed in [Table 2](#pone-0076113-t002){ref-type="table"} and detailed compositions of CHM of included studies were listed in [Table 3](#pone-0076113-t003){ref-type="table"}.

10.1371/journal.pone.0076113.t002

###### Summary of the characteristics of the included trials and the assessment of methodology.
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  First author year    Subjects (T/C)         Age (T/ C)          Duration of diabetes       Duration of DPN      Intervention   Main Outcome measures   Course of treatment (d)   Adverse events   Follow up  
  ------------------- ---------------- ------------------------ ------------------------ ----------------------- -------------- ----------------------- ------------------------- ---------------- ----------- ------
  Hu2012                   30/30        59.17±9.92/5 9.77±6.26    8.71±6.32/ 9.01±5.49    4.52±3.06/ 4.36±3.44        CHM             mecobalamin                  TER                  12w            4/0      n.r.
  Chen2011a                17/10        63.52±5.21/61.17±7.38             n.r.            5.63±5.35/5. 72±6.05/       CHM             mecobalamin               TER, NCV                12w            No       n.r.
  Chen2011b                 17/8        63.52±5.21/6 1.73±5.75            n.r.            5.63±5.35/3. 70±4.05        CHM               placebo                 TER, NCV                12w            No       n.r.
  Cao2011                  30/30        60.06±4.73/5 9.10±4.82    7.94±3.13/ 7.71±3.32    2.54±1.60/2. 63±2.09        CHM             mecobalamin               TER, NCV                 6w            No       n.r.
  Li 2011                  30/30        58.30±8.33/5 8.37±9.52    9.17±4.36/ 9.53±4.13            n.r.                CHM+        pancreatin tablets            TER, NCV                 8w            No       n.r.
  Zhou 2010                20/20        58.4±10.67/6 1.7±4.92             n.r.            5.85±2.71/4. 95±2.74        CHM             mecobalamin               TER, NCV                 8w            No.      n.r.
  Zhang 2008               38/36        61.19±8.59/6 1.67±9.22   10.77±4.78 /9.88±4.95    2.93±2.07/2. 61±2.22        CHM             mecobalamin                  TER                   8w            No.      n.r.
  Liu 2004                 24/24        56.33±7.73/5 5.04±6.61    7.35±3.91/. 48±3.73     2.63±2.08/2. 46±1.27        CHM              inositol                 TER, NCV                 8w            No       n.r.
  Heng 2004                60/60          55.5±6.3/54.8±6.6         7.7±3.2/7.6±2.9          2.3±1.6/2.3±1.5          CHM              inositol                 TER, NCV                 8w           19/20     n.r.
  Li 2005                  55/53         48.3±14.9/45 ±20.27      12.1±7.3vs 11.5±7.78       4.7±0.6/4.9±0.6          CHM             mecobalamin               TER, NCV                12w            No.      n.r.
  Liu 2005                 24/24        51.31±6.47/5 1.84±7.01   12.52±3.98 /11.31±3.05   4.52±1.21/4. 46±1.12        CHM             mecobalamin               TER, NCV                 8w            No       n.r.

Notes: T: Trial Group, C: Control Group, +: mean same as the control group treatment; TER: Total efficacy rate, NCV: Nerve conduction velocity; n.r.: not report; No: no adverse event was identified; Chen2011a: CHM compared with mecobalamin; Chen2011b: CHM compared with placebo.

10.1371/journal.pone.0076113.t003

###### Herbal medicines in the included studies.

![](pone.0076113.t003){#pone-0076113-t003-3}

  First author year              Name of Herbs             Formulation                                                                                                                                                                                                                                                                                     Compositions                                                                                                                                                                                                                                                                                           Usage
  ------------------- ----------------------------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Hu2012                  Guizhi Shaoyao Zhimu Tang\\       decoction                         cassia twig (Ramulus Cinnamomi), debark peony root (Radix Paeoniae Alba), ephedra (Herba Ephedrae), largehead atractylodes rhizome (Rhizoma Atractylodis Macrocephalae), common anemarrhena rhizome (Rhizoma Anemarrhenae), divaricate saposhnikovia root (Radix Saposhnikoviae), prepared common monkshood branched roo (Radix Aconiti Lateralis Preparata), fresh ginger (Rhizoma Zingiberis Recens), liquorice root (Radix Glycyrrhizae), suberect spatholobus stem (Caulis Spatholobi), danshen root (Radix Salviae Miltiorrhizae)                           100ml, Tid,
  Chen2011                  Xiaoke Tongluo Capsule           capsule                                                                                                                                                             milkvetch root (Radix Astragali seu Hedysari), red ginseng (Radix Ginseng Rubra), danshen root (Radix Salviae Miltiorrhizae), sanqi (Radix Notoginseng), unprocessed rehmannia root (Radix Rehmanniae Recens), peony root (Radix Paeoniae Rubra), leech (Hirudo)                                                                                                                                                            4 capsules, Tid,
  Cao2011                   YiqiWenyanghuoxue Tang          decoction                                                                              milkvetch root (Radix Astragali seu Hedysari), cassia twig (Ramulus Cinnamomi), sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong), earthworm (Lumbricus), suberect spatholobus stem (Caulis Spatholobi), peony root (Radix Paeoniae Rubra), debark peony root (Radix Paeoniae Alba), medicinal cyathula root (Radix Cyathulae), unprocessed rehmannia root (Radix Rehmanniae Recens), manchurian wildginger (Herba Asari)                                                                               100ml, Tid,
  Li 2011                   Buqi Huoxue Xiaobi Tang         decoction                                                                                                                                                                                       milkvetch root (Radix Astragali seu Hedysari), Chinese angelica (Radix Angelicae Sinensis), peony root (Radix Paeoniae Rubra), sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong), earthworm (Lumbricus)                                                                                                                                                                                        100ml, Tid,,
  Zhou 2010                  Tongluo Tangtai Tang           decoction                                                                                                                                 milkvetch root (Radix Astragali seu Hedysari), common yam rhizome (Rhizoma Dioscoreae), figwort root (Radix Scrophulariae), dwarf lilyturf tuber (Radix Ophiopogonis), danshen root (Radix Salviae Miltiorrhizae), sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong), suberect spatholobus stem (Caulis Spatholobi)                                                                                                                                   150ml, Tid
  Zhang 2008                  Tangluoning Capsule            capsule                                                                                                                                            milkvetch root (Radix Astragali seu Hedysari), unprocessed rehmannia root (Radix Rehmanniae Recens), cibot rhizome (Rhizoma Cibotii), twotoothed achyranthes root (Radix Achyranthis Bidentatae), danshen root (Radix Salviae Miltiorrhizae), sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong)                                                                                                                                             100ml, Bid
  Liu 2004                    Tangluotong Capsule            capsule                                                                                                                                                   leech (Hirudo), White Mustard Seed (semen brassicae), borneol (Borneolum Syntheticum), American ginseng (Radix Panacis Quinquefolii), Chinese angelica (Radix Angelicae Sinensis), yanhusuo (Rhizoma Corydalis), figwort root (Radix Scrophulariae), golden thread (Rhizoma Coptidis)                                                                                                                                                       n.r.
  Heng 2004                   Tangluotong Capsule            capsule                                                                                                                                                   leech (Hirudo), White Mustard Seed (semen brassicae), borneol (Borneolum Syntheticum), American ginseng (Radix Panacis Quinquefolii), Chinese angelica (Radix Angelicae Sinensis), yanhusuo (Rhizoma Corydalis), figwort root (Radix Scrophulariae), golden thread (Rhizoma Coptidis)                                                                                                                                                 2 capsules, Tid
  Li 2005                     Tangpingluotong Yin           decoction    milkvetch root (Radix Astragali seu Hedysari), heterophylly falsestarwort root (Radix Pseudostellariae), kudzuvine root (Radix Puerariae), unprocessed rehmannia root (Radix Rehmanniae Recens), leech (Hirudo), peony root (Radix Paeoniae Rubra), sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong), suberect spatholobus stem (Caulis Spatholobi), Chinese starjasmine stem (Caulis Trachelospermi), honeysuckle stem (Caulis Lonicerae), twotoothed achyranthes root (Radix Achyranthis Bidentatae), peach seed (Semen Persicae), frankincense (Olibanum), myrrh (Myrrha)     100ml, Tid,
  Liu 2005             Modified Huangqi Guizhi Wuwu Tang    decoction                                                                                                                                                          milkvetch root (Radix Astragali seu Hedysari), cassia twig (Ramulus Cinnamomi), peony root (Radix Paeoniae Rubra), earthworm (Lumbricus), suberect spatholobus stem (Caulis Spatholobi), common yam rhizome (Rhizoma Dioscoreae), liquorice root (Radix Glycyrrhizae)                                                                                                                                                           100ml, Tid,

Description of the CHMs {#s3c}
-----------------------

Thirty-nine herbs were included in the 10 studies with Jadad scored ≥3. The top 11 most frequently used herbs were ordinally milkvetch root (Radix Astragali seu Hedysari), suberect spatholobus stem (Caulis Spatholobi), peony root (Radix Paeoniae Rubra), sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong), danshen root (Radix Salviae Miltiorrhizae), leech (Hirudo), unprocessed rehmannia root (Radix Rehmanniae Recens), cassia twig (Ramulus Cinnamomi), earthworm (Lumbricus), Chinese angelica (Radix Angelicae Sinensis), figwort root (Radix Scrophulariae), which were used more than 3 times ([Table 4](#pone-0076113-t004){ref-type="table"}).

10.1371/journal.pone.0076113.t004

###### Analysis of the top 11 frequency Chinese herb medicine in treatment of diabetic peripheral neuropathy.

![](pone.0076113.t004){#pone-0076113-t004-4}

  Herb name English (Latin)                                  Frequency   The total frequency %   Cumulative percentiles %
  --------------------------------------------------------- ----------- ----------------------- --------------------------
  ordinally milkvetch root (Radix Astragali seu Hedysari)        7               8.43                      8.43
  suberect spatholobus stem (Caulis Spatholobi)                  5               6.03                     14.46
  peony root (Radix Paeoniae Rubra)                              5               6.03                     20.49
  sichuan lovage rhizome (Rhizoma Ligustici Chuanxiong)          5               6.03                     26.52
  danshen root (Radix Salviae Miltiorrhizae)                     4               4.82                     31.34
  leech (Hirudo)                                                 4               4.82                     36.16
  unprocessed rehmannia root (Radix Rehmanniae Recens)           4               4.82                     40.98
  cassia twig (Ramulus Cinnamomi)                                3               3.61                     44.59
  earthworm (Lumbricus)                                          3               3.61                     48.20
  Chinese angelica (Radix Angelicae Sinensis)                    3               3.61                     51.81
  figwort root (Radix Scrophulariae)                             3               3.61                     55.42

Risk of Bias within Studies {#s3d}
---------------------------

The methodological quality of each study was assessed using the Jadad score and all the included trials appeared to have a high quality with Jadad score varing from 3 to 5. And the risk of bias was further assessed using the twelve criteria recommended by the Cochrane Back Review Group. The number of criteria met varied from 6/12 to 10/12, which indicating that all of the included trials having a low risk of bias based on the Cochrane Risk of Bias tool. More details on the scores for each trial were present in [Table 5](#pone-0076113-t005){ref-type="table"}.

10.1371/journal.pone.0076113.t005

###### The methodological quality of the included trials.
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  First author year    12-item criteria        Jadad scale                                                                      
  ------------------- ------------------ ---- ------------- ---- --- ---- ---- --- ---- ---- ---- ---- ---- --- --- --- --- --- ---
  Hu2012                      \+          \+       \-        \-   ?   \+   \+   ?   \+   \+   \+   \+   8    1   1   0   0   1   3
  Chen2011                    ?           ?        \+        \+   ?   \-   \+   ?   \+   \+   \+   \+   7    1   0   1   1   1   4
  Cao2011                     \+          ?        \+        ?    ?   \-   \-   ?   \+   \+   \+   \+   6    1   1   1   0   0   3
  Li 2011                     \+          ?        \-        \-   ?   \+   \+   ?   \+   \+   \+   \+   7    1   1   0   0   1   3
  Zhou 2010                   \+          ?        \-        \-   ?   \-   \+   ?   \+   \+   \+   \+   6    1   1   0   0   1   3
  Zhang 2008                  \+          ?        \-        \-   ?   \-   \+   ?   \+   \+   \+   \+   6    1   1   0   0   1   3
  Liu 2004                    \+          \+       \+        \+   ?   \-   \-   ?   \+   \+   \+   \+   8    1   1   1   1   0   4
  Heng 2004                   \+          \+       \+        \+   ?   \+   \+   ?   \+   \+   \+   \+   10   1   1   1   1   1   5
  Li 2005                     \+          ?        \-        \-   ?   \-   \+   ?   \+   \+   \+   \+   6    1   1   0   0   1   3
  Liu 2005                    \+          ?        \-        \-   ?   \-   \+   ?   \+   \+   \+   \+   6    1   1   0   0   1   3

A to L, the 12-item criteria. A, adequate sequence generation; B, concealment of allocation; C, blinding (patient); D, blinding (investigator); E, blinding (assessor); F, incomplete outcome data addressed (ITT analysis); G, incomplete outcome data addressed (drop-outs); H, free of selective reporting; I, similarity at baseline; J, co-interventions constant; K, compliance acceptable; L, timing outcome assessments.

a to e, the Jadad scale. Points were awarded as follows: a, study was described as randomized, 1 point; b, appropriate randomization method, 1 point; c, study described as double-blinded, 1 point; d, appropriate double-blinded method, 1 point; e, description of withdrawals and dropouts, 1 point. The Jadad scale score ranges from 1 to 5; higher scores indicate better quality of the randomized controlled trial (RCT). T total.

Effectiveness {#s3e}
-------------

Nerve conduction velocity (NCV) was observed in 8 [@pone.0076113-Chen4]--[@pone.0076113-Zhou1], [@pone.0076113-Liu1]--[@pone.0076113-Liu2] of the 10 included studies, including 7 CHM monotherapy studies [@pone.0076113-Chen4]--[@pone.0076113-Cao1], [@pone.0076113-Zhou1], [@pone.0076113-Liu1]--[@pone.0076113-Liu2] and 1 CHM adjuvant therapy study [@pone.0076113-Li1]. Four CHM monotherapy studies compared the effect on median motor nerve conduction velocity (MMNCV) with the mecobalamin control \[37a, 38, 44--45\] and 1 with the placebo control \[37b\], the combined effects showed that CHM had a significantly better effect on MMNCV than mecobalamin control (n = 243, mean difference (MD) 1.63, 95% CI: −0.68--3.94, P = 0.17, heterogeneity chi-square  = 13.99, P = 0.003, I^2^ = 79%) and placebo control (MD 1.65; 95% CI −1.24 to 4.54). The combined effects showed that CHM monotherapy \[37a, 38, 40, 44--45\] had a significantly better effect on median sensory nerve conduction velocity (MSNCV) when compared with mecobalamin (n = 283, MD 1.68, 95% CI: −0.60--3.97, P = 0.15, heterogeneity chi-square  = 13.56, P = 0.009, I^2^ = 71%) but not a favorable effect when compared with placebo \[37b\] (MD −2.94; 95% CI −10.51 to 4.63) ([Figure 2](#pone-0076113-g002){ref-type="fig"}). Three CHM monotherapy studies [@pone.0076113-Cao1], [@pone.0076113-Li2]--[@pone.0076113-Liu2] compared the effect on peroneal motor nerve conduction velocity (PMNCV) with the mecobalamin control group, the combined effects showed that CHM had a significantly better effect on PMNCV (n = 168, MD 2.81, 95% CI: 2.19--3.44, P\<0.00001, heterogeneity chi-square  = 0.31, P = 0.86, I^2^ = 0%). One CHM adjuvant therapy study [@pone.0076113-Li1] compared the effect on PMNCV with the pancreatin tablets and the result showed that CHM had a significantly better effect on PMNCV (MD 4.91; 95% CI 3.48 to 6.34). 8 CHM monotherapy studies compared the effect on peroneal sensory nerve conduction velocity (PSNCV) with the mecobalamin \[37a, 38, 40, 44--45\] or placebo \[37b\] or inositol [@pone.0076113-Liu1], [@pone.0076113-Heng1] control group, the combined effects showed that CHM had a significantly better effect on PSNCV than mecobalamin control (n = 283, MD 3.95, 95% CI: 2.22--5.67, P\<0.00001, heterogeneity chi-square  = 7.73, P = 0.10, I^2^ = 48%) and inositol control (n = 168, MD 1.31, 95% CI: 0.16--2.45, P = 0.03, heterogeneity chi-square  = 0.77, P = 0.38, I^2^ = 0%) except placebo control (MD −1.23; 95% CI −5.57 to 3.11). The CHM adjuvant therapy study [@pone.0076113-Li1] compared the effect on PSNCV with t pancreatin tablets control group showed that CHM had a significantly better effect on PSNCV (MD 0.79; 95% CI 0.34 to 1.24) ([Figure 3](#pone-0076113-g003){ref-type="fig"}). The publication bias funnel plot provided evidence of publication bias ([Figure 4](#pone-0076113-g004){ref-type="fig"} and [Figure 5](#pone-0076113-g005){ref-type="fig"}).
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Total efficacy rate were assessed in all the 10 included studies, including 9 CHMs monotherapy studies and 1 CHM adjuvant therapy study. The combined effects showed that CHM monotherapy had a significantly total efficacy rate when compared with mecobalamin [@pone.0076113-Hu1]--[@pone.0076113-Cao1], [@pone.0076113-Zhou1]--[@pone.0076113-Zhang3], [@pone.0076113-Li2]--[@pone.0076113-Liu2] (n = 417, relative risk (RR): 1.31, 95% confidence interval (CI): 1.16--1.48, P\<0.00001, heterogeneity chi-square  = 7.59, P = 0.27, I^2^ = 21%) and inositol [@pone.0076113-Liu1], [@pone.0076113-Heng1] control (n = 168, RR 1.66, 95% CI 1.26--2.19, P = 0.0003, heterogeneity chi-square  = 0.64, P = 0.42, I^2^ = 0%). However, CHM monotherapy did not show a favorable effect on total efficacy rate when compared with placebo [@pone.0076113-Chen4] (RR 0.87; 95% CI 0.60 to 1.27). In CHM adjuvant therapy study, Li et al. [@pone.0076113-Li1] indicated that CHM adjuvant therapy had a significantly better effect on total efficacy rate than pancreatin tablets (RR 1.56; 95% CI 1.14 to 2.12) ([Figure 6](#pone-0076113-g006){ref-type="fig"}). The publication bias funnel plot provided evidence of publication bias ([Figure 7](#pone-0076113-g007){ref-type="fig"}).
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Adverse effects were reported in all of the included studies, and no life threatening adverse effects were noted in all studies. Most of the trials (8/10) mentioned that no obvious adverse effects were found both in CHM group and control group. One study [@pone.0076113-Hu1] reported that 4 cases suffered from upset and sweating in CHM group, and no obvious adverse effects were found in control group. Another study reported that side effects were 31.7% and 33.3% for CHM monotherapy and inositol control respectively [@pone.0076113-Heng1], including mild abdominal pain, diarrhea, nausea, chest discomfort. The above results suggested that CHM monotherapy and adjuvant therapy were relatively safe for DPN.

Discussion {#s4}
==========

Summary of Evidence {#s4a}
-------------------

This study is the update meta-analysis of English and Chinese literature to determine the efficacy and safety of CHM for DPN. One hundred and sixty-three studies claimed RCTs. Ten high quality studies with 653 individuals were identified based on the Jadad score ≥3. The main findings were that CHM monotherapy and adjuvant therapy could improve the clinical symptoms and NCV of DPN, and had fewer adverse effects in comparison with WCM controls. Despite of the apparently positive findings, it is premature to conclude the efficacy of CHMs for the treatment of DPN because of the high clinical heterogeneity of the included studies and small number of trials in the meta-analysis. Adverse effects were reported in all of the included studies, and CHM used generally appeared to be safe and well tolerated in patients with DPN in all studies. Thus, we can make it as a conclusion that CHMs therapy was safe for DPN.

Limitations {#s4b}
-----------

There are a number of limitations to this review. Firstly, none of included studies had been registered. In September 2004, the members of the International Committee of Medical Journal Editors (ICMJE) published a statement requiring that all clinical trials must be registered in order to be considered for publication [@pone.0076113-DeAngelis1]. However, none of included studies in this review had been formally registered in WHO International Clinical Trials Registry Platform. Thus, protocols were not available to confirm free of selective reporting.

Secondly, although the methodological quality of the included RCTs was generally high according to the Jadad scale and the twelve criteria recommended by the Cochrane Back Review Group, there were still some methodological weaknesses in the primary studies. Most of the included studies (9/10) provided sufficient information on how the random allocation was generated, but only 3 trials described allocation concealment, which may produce selection bias. Four-tenth studies mentioned subjects blinding, and 4/10 mentioned investigator while no study described assessor blinding. Only 3/10 studies described intention-to-treat analyses, and no study reported follow-up data. Therefore, the results generated from these studies should be interpreted with caution.

Thirdly, among the 10 included studies, only one [@pone.0076113-Chen4] used a formal placebo control. All of the left 9 studies included in this review used an ''A or A + B versus B'' design in which patients were randomized to receive a CHM monotherapy or an adjuvant therapy with CMH plus WCM versus WCM control treatment, without a rigorous control for placebo effect. Because of the lack of placebo controls, the interpretation of the positive findings of treatment with CHM should be made with caution.

Fourthly, clinical efficacy rate was used as the major outcome measures to show effectiveness in this review, which was measured through subjective qualitative scores such as "cure", "significant improvement", "improvement", and "no improvement". The 4 classifications for overall symptom improvement as an outcome measure were commonly used in Chinese trials but not internationally recognized, which may limit the validity and reliability of the outcome. Moreover, the time of the measurement was different among the trials, which leads to difficulties in interpreting the effects. Nerve conduction velocity was another weakness in the primary studies. All of the included studies adopted the treatment duration of 6--12 weeks. We should be cautiously interpret this outcome because it was more reliable if the changing of NCV was measured when the treatment duration lasted more than 12 weeks. At last, all the studies met the criteria coming from China was another weakness that potentially limited the generalizability of the findings.

Fifthly, the clinical heterogeneity compromised the validity of the included studies. There were large variations in the formulation, dosage, administration, and duration of treatment in the CHM of included studies. Moreover, several forms of CHM were tested in the included studies lacking detailed information about quality control for manufacturing methods and standards of CHM, which is crucial for the validity of the study results. Future studies should provide sufficient information about standardization in terms of formulation, quality control, purity, dosage, administration, and duration of treatment [@pone.0076113-Gagnier1].

Sixthly, most of the included studies were of relatively small sample size and without formal sample size estimation. Trials with inadequate sample sizes often run the risk of overestimating intervention benefits [@pone.0076113-Kjaergard1]. The results were likely to be underpowered [@pone.0076113-Wang2].

Implications for practice {#s4c}
-------------------------

This is update systematic review of randomized, controlled trials to assess the efficacy and safety of CHM for DPN. Due to the high clinical heterogeneity of the included studies and the small sample sizes of trials included in this systematic review, the current evidence is insufficient to recommend the routine use of CHM for DPN. However, CHMs appeared to be well tolerated in all included studies. Thus, CHM therapy was safe for DPN. However, all trials were performed only on Chinese people. No trials testing the drug on other ethnic groups were found. Thus, the results may have limitations for generalizing to populations out of China.

Implications for research {#s4d}
-------------------------

CHM is widely used in the treatment of DPN. Although the present evidence is insufficient for support efficacy of CHM, it is a promising candidate for further clinical trial of DPN. The most frequently used herbs such as milkvetch root, Chinese angelica, sichuan lovage rhizome, peony root, danshen root, earthworm, suberect spatholobus stem, safflower, cassia twig, unprocessed rehmannia root, peach seed, liquorice root, kudzuvine root, leech, debark peony root may contribute in composing a fundamental prescription for clinical DPN treatment. Since the concern in methodological quality, we recommend that the CONSORT 2010 statement [@pone.0076113-Schulz1], [@pone.0076113-Moher1], which consists of a 25-item checklist to determine study quality and rigor, should be used as a guideline when further designing and reporting RCTs. In addition, sufficient information about formulation, quality of the preparations, purity, dosage, administration, and duration of treatment should be provided in future studies [@pone.0076113-Gagnier1].

Conclusion {#s5}
==========

In spite of the apparently positive findings based on the 10 high quality studies, there is insufficient evidence regarding the efficacy of CHM for the treatment of DPN because of the high clinical heterogeneity of the included studies and small sample sizes of the included trials. Adverse effects were reported in all of the included studies, and CHM was generally safe. Therefore, we can arrive at a conclusion that CHM therapy was safe for DPN. Further standardized preparation, large sample-size and rigorously designed RCTs are required.
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